Key Highlights
- STAAR Surgical shares rose 3.46% pre-market today to $28.11, from a prior close of $27.17.
- Third-quarter net sales of $83.4 million beat the $78.7 million estimate.
- Excluding prior-year deferred China sales, net sales grew 21%, with China up 31% to $39.3 million.
- Sales outside China rose 13% to $44.1 million, led by 31% growth in EMEA.
- Cash and investments stood at $206.4 million with no debt, alongside a new $50 million buyback.
STAAR Surgical (NASDAQ:STAA) shares rose in pre-market activity today after third-quarter results topped sales expectations and the board authorized a $50 million share repurchase program. The stock changed hands at $28.11, up 3.46% from Wednesday's close of $27.17, which followed a 7.95% gain in the regular session.
STAAR is a Lake Forest, California-based maker of implantable phakic intraocular lenses. Its EVO family of Implantable Collamer Lenses corrects myopia, hyperopia, astigmatism and presbyopia without removing corneal tissue. The company has sold more than 4 million lenses in over 75 countries, and about 95% of its Revenue comes from outside the United States, with China a major growth driver.
Reported net sales of $83.4 million fell 12% from a year earlier because the prior-year quarter included $25.9 million of deferred China sales. Excluding those, sales grew 21%.
China Pricing and Toric Mix Lift Growth While Supply Limits Fulfillment
China net sales were $39.3 million, up 31% excluding the deferred sales, with all of the growth coming from higher average selling prices on EVO Plus and toric lenses. Distributor unit shipments in China grew 12.4% through nine months, and supply constraints limited fulfillment of lens demand.
Outside China, net sales rose 13% to $44.1 million. EMEA grew 31%, or 51% excluding the Middle East, and the Americas grew 14%. Asia Pacific excluding China grew 4%, with Japan declining on currency and South Korea on market weakness. U.S. sales topped $6 million for a third straight quarter.
Gross Margin Slips on Tariffs and System Costs as Buyback Arrives
Gross margin was 70.9% versus 75.5% in the prior-year quarter excluding deferred China sales. Pressures included ERP implementation, freight, tariffs and inventory provisions. Management expects fourth-quarter gross margin above the third quarter and further improvement in 2027 as the Swiss and U.S. plants run at full capacity, with each point of Manufacturing Yield improvement adding roughly $750,000 to $1 million of annual gross profit. A planned shift of China manufacturing to Switzerland cuts Tariff exposure.
Operating expenses were $53.7 million, and the company remains on track for its $225 million adjusted Operating Expense target. GAAP Net Income was $5.6 million, or $0.11 per diluted share, and adjusted EBITDA was $14.4 million. Stifel raised its price target to $34 from $31.
STAAR carries a market Capitalization of about $1.36 billion and a forward price-to-earnings ratio of 50.00. Its 52-week range runs from $15.59 to $35.87. The new $50 million repurchase program follows a quarter-end cash and investments balance of $206.4 million.
No Fourth-Quarter or 2027 Guidance Leaves Pipeline Milestones in Focus
Management gave no fourth-quarter or 2027 guidance. Fourth-quarter China sales are expected to be seasonally lower than the third quarter but higher than last year, and management expects strong full-year GAAP net income and free cash flow.
First-in-human trials for two Collamer-based presbyopia lenses are expected to begin enrollment in the next few months, pending regulatory approvals. The company aims for a major product launch every 18 to 24 months, and recent label expansions in the U.S. (age 60) and Brazil (-0.5 diopters) widen the eligible patient pool.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...